Polypharmacy in schizophrenia: A fuzzy concept [3] (multiple letters)

Journal of Clinical Psychiatry

Volumn 64, Issue 9, 2003, Pages 1132-1135

  Freudenreich, Oliver ^a   Goff, Donald C ^a   Stahl, Stephen M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NEUROSCIENCE EDUCATION INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; VALPROATE SEMISODIUM;

CLINICAL PRACTICE; COMORBIDITY; CONCEPT FORMATION; COST BENEFIT ANALYSIS; DECISION MAKING; DEPRESSION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HUMAN; LETTER; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RESOURCE ALLOCATION; SCHIZOPHRENIA; SMOKING CESSATION; SOCIOECONOMICS; THEORY;

EID: 0141493853     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0921d     Document Type: Letter

References (0)